Early study shows Ebola vaccine to be safe
the ONA take:
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China, a new study published in the journal The Lancet has shown.
The Phase 1 study evaluated the safety of the vaccine in 120 healthy people in China's Jiangsu province. Participants received either a low dose or high dose of the vaccine, or placebo.
Participants were then monitored for over 28 days for any adverse events and an immune response. Results showed that no serious adverse events occurred and antibodies were significantly increased in participants.
Although the study did not demonstrate whether the immune response lasted longer than 28 days or whether a booster immunization would be needed, researchers say that the vaccine has potential.
Ad5-EBOV is not the only vaccination being studied to combat the Ebola virus, which has killed more 10,000 people since the beginning of 2014.
Other vaccines are currently in Phase III testing where they are being used in people at risk of infection in west Africa. The United Nations Ebola response team said this week that the Ebola outbreak should be gone by this summer.
The Ad5-EBOV Ebola virus vaccine was proven safe in an early study in healthy adults in China.
- Novel Blood Test Detects Cancer, Locates Tumor Without Invasive Procedures
- Cabozantinib Activates Innate Immune Response, Eliminating Prostate Cancer
- Shorter Treatment of Breast Cancer with Trastuzumab May Lead to Improved Results
- Colorectal Cancer Rates Increased Sharply Among Generation X and Millennials
- Pneumonia Associated With Common Cold May Cause Fatal Illness in Stem Cell Transplant Recipients
- Early Palliative Care Reduced ICU Use in Patients With Advanced Cancer
- Ginger Extract Raises Antioxidant Levels in Patients Undergoing Chemotherapy
- Nurse Navigators Improve Physician Engagement in Pretreatment Discussions
- Screening Increases Early Palliative Care, Reduces Aggressive EOL Measures
- Antiperspirants/Deodorants and Breast Cancer (Fact Sheet)
- Genome Sequencing Explains Resistance to CTLA-4 and PD-1 Inhibitors in Metastatic Melanoma
- Lifestyle Choices Have Greater Influence on Colon and Rectal Cancer Risk
- Kidney Cancer Metastases in Lung May Hide Undiagnosed Primary Lung Cancer
- Nasal Biomarker in Smokers Could Predict Lung Cancer
- Arm Lymphoscintigraphy After Axillary Lymph Node Dissection or Sentinel Lymph Node Biopsy in Breast Cancer
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|